Overview
RheoSense develops compact viscometers and rheometers built on a chip (VROC) that use MEMS and microfluidics to measure viscosity with very small sample volumes. Their m-VROC and microVISC instruments provide direct readings of viscosity and rheological properties in a user-friendly package. The core idea is to combine a microfabricated viscometer and rheometer on a single chip to enable fast, precise measurements with minimal sample consumption. RheoSense differentiates itself from competitors through patented VROC technology, a focus on very small samples, and a strong footprint in biotechnology, pharmaceutical, and protein therapeutics markets, with adoption by Fortune Global 500 companies and leading research universities. The company aims to widen access to accurate viscometry and rheology for drug development, quality control, and research by offering easy-to-use, reliable instruments that reduce sample requirements and processing time.
Work here?Claim your company
Simplify's take
What believers are saying
- RheoSense launched m-VROC II, VROC initium 1++, and Chip Cleaning Station in 2026.
- RheoSense’s 2026 content emphasizes biopharma workflows, especially monoclonal antibodies and injectability testing.
- Government and lab usage continues, including a 2024 NIH m-VROC II purchase.
What critics are saying
- Anton Paar and Malvern crush RheoSense with broader portfolios and distribution reach.
- No disclosed venture financing leaves RheoSense undercapitalized for manufacturing, sales, and R&D scale.
- If biopharma accounts standardize on rival platforms, RheoSense becomes a niche instrument supplier.
What makes RheoSense unique
- RheoSense’s VROC chips measure viscosity from 10-19 µL samples with retrieval and reuse.
- The 2026 VROC initium 1++ automates 96-sample screening, cleaning, and temperature sweeps.
- The 2026 Chip Cleaning Station cleans m-VROC and microVISC chips under 10 minutes.
Help us improve and share your feedback! Did you find this helpful?